<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>jmedicalcasereports</PublisherName>
<JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Volume 3; Issue 3</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>(May-Jun, 2022)</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>Medical Case Reports</ArticleType>
<ArticleTitle>Guillain–Barr__ampersandsigneacute; Syndrome with MFS and AMSAN Variants: A Rare Case</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>1</FirstPage>
<LastPage>7</LastPage>
<AuthorList>
<Author>
<FirstName>Afnan. W. M.</FirstName>
<LastName>Jobran</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Ranin F. F.</FirstName>
<LastName>Alawi</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Majd A.</FirstName>
<LastName>AbuAlrob</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Anis Munir</FirstName>
<LastName>Naser</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Background: The immunologically mediated polyneuropathies Guillain–Barr__ampersandsigneacute; syndrome (GBS) and Guillain–Barr__ampersandsigneacute; syndrome (GBS) are important clinically. It is assumed to have a hereditary component, although no genetic risk locus has been identified. It__ampersandsign#39;s thought to be autoimmune, but the causes are unknown. It might be generated by molecular mimicry, such as from pathogens and vaccines, but hosting factor and co-founding host reactions would undoubtedly alter disease incidence and course. Case Presentation: A 57 year old female, three weeks after influenza vaccination she started complaining of double vision, left eye ptosis, dizziness, and bilateral symmetric upper and lower extremities weakness which described as “feeling sleepy”, both proximal and distal muscles are equally affected. The patient sought medical advice, ophthalmology examination and radiological imaging were free. Conclusion: AMSAN is recently identified GBS variant characterized by sensory symptoms, loss of deep tendon reflexes, and distant weakness with immediate onset.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Guillain–Barré,Immune Response,Axonal Neuropathy,Polyradiculoneuropathy</Keywords>
<URLs>
<Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13716&title=Guillain–Barr__ampersandsigneacute; Syndrome with MFS and AMSAN Variants: A Rare Case</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Anthony SA, Thurtell MJ, Leigh RJ. Miller Fisher syndrome mimicking ocular myasthenia gravis. Optom Vis Sci 2012; 89: e118-e123.
Asbury AK and Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barrand;eacute; syndrome. Ann Neurol 1990; 27: S21-S24.
Asbury AK. Criteria for diagnosis of Guillain-Barrand;eacute; syndrome. Ann Neurol 1978; 3: 565-566.
Bukhari S and Taboada J. A case of Miller Fisher syndrome and literature review. Cureus 2017; 9: e1048.
Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997; 745: 32-36.
Chowdhury D and Arora A. Axonal Guillain–Barrand;eacute; syndrome: a critical review. Acta Neurol Scand 2001; 103: 267-277.
Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW. An acute axonal form of guillain-barrand;eacute;e polyneuropathy. Brain 1986; 109: 1115-1126.
Gupta SK, Jha KK, Chalati MD, Alashi LT. Miller Fisher syndrome. BMJ Case Rep 2016; 2016: bcr2016217085.
Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV, Plasma Exchange/Sandoglobulin Guillain-Barrand;eacute; Syndrome Trial Group. Electrophysiological classification of Guillain-Barrand;eacute; syndrome: clinical associations and outcome. Ann Neurol 1998; 44: 780-788.
Jacobs BC, Endtz HP, van der Mechand;eacute; FG, Hazenberg MP, Achtereekte HA, van Doorn PA. Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995; 37: 260-264.
Jacobs BC, van Doorn PA, Tio-Gillen AP, Visser LH, van der Mechand;eacute; FG, Schmitz PI, Herbrink P, Hooijkaas H. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barrand;eacute; syndrome. Ann Neurol 1996; 40: 181-187.
Kuijf M, Ruts L, van Doorn PA, Koudstaal PJ, Jacobs BC. Diagnostic value of anti-GQ1b antibodies in a patient with relapsing dysarthria and ataxia. BMJ Case Rep 2009; 2009: bcr0820080783.
Kuwabara S, Ogawara K, Mizobuchi K, Koga M, Mori M, Hattori T, Yuki N. Isolated absence of F waves and proximal axonal dysfunction in Guillain-Barre syndrome with antiganglioside antibodies. J Neurol Neurosurg Psychiatry 2000; 68: 191-195.
Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001; 56: 1104-1106.
Overell JR and Willison HJ. Recent developments in Miller Fisher syndrome and related disorders. Curr Opin Neurol 2005; 18: 562-566.
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barrand;eacute; syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123-133.
Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, Burwen DR, Cornblath DR, Cleerbout J, Edwards KM, Heininger U. Guillain-Barrand;eacute; syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29: 599-612.
Visser LH, Van der Mechand;eacute; FG, Van Doorn PA, Meulstee J, Jacobs BC, Oomes PG, Kleyweg RP. Guillain-Barrand;eacute; syndrome without sensory loss (acute motor neuropathy) A subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995; 118: 841-847.
Vucic S, Kiernan MC, Cornblath DR. Guillain-Barrand;eacute; syndrome: an update. J Clin Neurosci 2009; 16: 733-741.
Yepishin IV, Allison RZ, Kaminskas DA, Zagorski NM, Liow KK. Miller Fisher syndrome: a case report highlighting heterogeneity of clinical features and focused differential diagnosis. Hawaii J Med Public Health 2016; 75: 196-199.
Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci 1999; 168: 121-126.
Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barrand;eacute; and Fisher syndromes. Lancet Infect Dis 2001; 1: 29-37.
Yuki N. Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barrand;eacute; syndrome and Miller Fisher syndrome. J Infect Dis 1997; 176: S150-S153.</References>
</References>
</Journal>
</Article>
</ArticleSet>